You are here

breast cancer

Novartis drug helps stop breast cancer’s return in large study

Novartis drug helps stop breast cancer’s return in large study

BioPharma Dive

clinical trials

Flag link:

Byondis' breast cancer drug fails to bloom as FDA denies approval

Byondis' breast cancer drug fails to bloom as FDA denies approval

Fierce Biotech

antibody-drug conjugate

HER-2 positive breast cancer

Flag link:

Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect

Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect

Fierce Biotech

brain metastases

Flag link:

Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec

Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec

Fierce Pharma

Flag link:

OncoRix's breast cancer integrative solution demonstrated enhanced efficacy when combined with chemotherapy in an ex-vivo model

OncoRix's breast cancer integrative solution demonstrated enhanced efficacy when combined with chemotherapy in an ex-vivo model

BioSpace

Flag link:

Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

BioSpace

clinical trials

Flag link:

Olema Oncology to cut 25% of staff, says it will focus on late-stage pipeline

Olema Oncology to cut 25% of staff, says it will focus on late-stage pipeline

Endpoints

Flag link:

FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

Fierce Pharma

Flag link:

Aileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924

Aileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924

NASDAQ

Aileron Therapeutics

clinical trials

Flag link:

Next phase of breast cancer vaccine research begins at Cleveland Clinic

Next phase of breast cancer vaccine research begins at Cleveland Clinic

WKYC

Cleveland Clinic

triple negative breast cancer

Flag link:

Gilead's Trodelvy snags vital breast cancer nod

Gilead's Trodelvy snags vital breast cancer nod

Fierce Pharma

Gilead Sciences

HR-positive HER-negative breast cancer

Flag link:

In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion

In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion

Fierce Pharma

Flag link:

Menarini shows Big Pharma how it's done with first approval for oral SERD drug in breast cancer

Menarini shows Big Pharma how it's done with first approval for oral SERD drug in breast cancer

Fierce Pharma

Flag link:

5 FDA decisions to watch in the first quarter

5 FDA decisions to watch in the first quarter

BioPharma Dive

Alzheimer's disease

Acadia Pharmaceuticals

Gilead Sciences

Flag link:

FDA says yes to MedCognetics breast cancer screening AI

FDA says yes to MedCognetics breast cancer screening AI

Pharmaphorum

artificial intelligence

Flag link:

AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials

AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials

Clinical Trials Arena

clinical trials

datopotamab deruxtecan

metastatic triple-negative breast cancer

Flag link:

SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla

SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla

Fierce Pharma

Flag link:

Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate

Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate

Fierce Biotech

antibody-drug conjugate

clinical trials

Gilead Sciences

Flag link:

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

BioSpace

Myriad Genetics

genetic testing

Flag link:

Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial

Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial

BioSpace

clinical trials

Flag link:

Pages